{
  "docId": "019dd923-622b-71dc-a6da-84595e2c37a3",
  "docSlug": "08680a75fcb3",
  "documentTitle": "Pfizer Inc. (PFE)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 74,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 42,
  "notes": "The chart highlights that even when excluding COVID-related revenue, Pfizer (PFE) and PFE Excl. COVID underperform the peer median.",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "bar_chart_vertical",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/39",
  "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "callout",
      "text": "We believe the Company should seek to improve R&D and innovation to improve growth prospects.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "486f218c-6526-4572-96a8-62125c870f79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.92,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Ex-LOE Revenue Growth (2023 to 2030)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bb59aa0-aca0-4d8e-9a7c-52eade110ca2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Ex-LOE Revenue Growth: 23%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-e6eb-753a-a394-c9c5083e4ecc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Accounting for sizable patent expirations further highlights Pfizer's lagging gross revenue growth relative to peers.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8850aeda-394e-42f7-9b7d-6dc1bd1f65bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Visible Alpha, Bloomberg, and Wall Street research. (1) Based on Starboard's research and estimates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44fb925e-9388-4fad-a0ea-3465a897c703",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.92,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Even Excluding Pfizer's Large Patent Expirations, the Company Is Still Expected to Underperform on Growth",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49452be6-185d-44cd-accf-366d491cc76f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Slide recipe: the peer-gap chart",
      "slug": "peer-gap-chart-recipe",
      "agent": "designer",
      "layer": "slide",
      "matchId": "4bbb3d9f-7724-4bed-ad25-c55bfcc69067",
      "evidence": "This slide compares Pfizer's revenue growth to that of its peers, excluding patent expirations, which is a key component of a peer gap chart.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "0ecfa6fd-26df-4e5f-aebd-0eed5e585fed",
      "evidence": "Comparing PFE growth metrics against a peer group median.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 73,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07",
      "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.",
      "position": 0,
      "objective": "What are the costs of inaction for Pfizer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 71,
      "from": 11,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f",
      "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.",
      "position": 1,
      "objective": "How can Pfizer improve its performance?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}